Jefferies Group LLC Mannkind Corp Transaction History

Jefferies Group LLC

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 May 16, 2022	SELL	$2.62 - $4.45 $98,857 - $167,907	-37,732 Closed	0 $0
Q4 2021 Feb 14, 2022	BUY	$4.05 - $5.37 $152,814 - $202,620	37,732 New	37,732 $74,000
Q1 2020 May 15, 2020	SELL	$0.84 - $1.76 $53,814 - $112,754	-64,065 Closed	0 $0
Q4 2019 Feb 13, 2020	BUY	$1.14 - $1.49 $72,098 - $94,233	63,244 Added 7703.29%	64,065 $83,000
Q3 2019 Nov 13, 2019	SELL	$1.04 - $1.44 $304 - $421	-293 Reduced 26.3%	821 $1,000
Q2 2019 Aug 14, 2019	SELL	$1.09 - $1.88 $990 - $1,708	-909 Reduced 44.93%	1,114 $1,000
Q1 2019 May 15, 2019	BUY	$1.14 - $2.25 $448 - $884	393 Added 24.11%	2,023 $4,000
Q4 2018 Feb 14, 2019	BUY	$1.02 - $2.05 $90 - $182	89 Added 5.78%	1,630 $2,000
Q3 2018 Nov 14, 2018	BUY	$1.01 - $2.19 $1,556 - $3,374	1,541 New	1,541 $3,000
Q2 2018 Aug 14, 2018	SELL	$1.59 - $2.38 $59,625 - $89,250	-37,500 Closed	0 $0
Q1 2018 May 15, 2018	BUY	$2.28 - $3.8 $85,499 - $142,500	37,500 New	37,500 $86,000

219

133M

1.43M

851K

Ticker MNKD
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 257,338,000
Market Cap $1.6B
Description
MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes. It also promotes Thyquidity to adult and pediatric endocri...

Get notified when there are updates to the investment portfolio of Jefferies Group LLC, based on Form 13F filings with the SEC.

Stay updated on Jefferies Group LLC with notifications on news.